New Amsterdam May 2026

: Improved slightly to a net loss of $203.8 million for 2025, compared to $241.6 million in 2024 .

: Reported earnings of €0.47 per ordinary share . Entertainment: NBC's "New Amsterdam" TV Series New Amsterdam

: Ongoing heavy investment in the development of obicetrapib . Finance: New Amsterdam Invest N.V. : Improved slightly to a net loss of $203

: Reported $728.9 million in cash and equivalents as of December 31, 2025, a decrease from the previous year due to R&D spending . New Amsterdam